Elevation Oncology (ELEV) Competitors $0.58 -0.05 (-7.30%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ELEV vs. PBYI, TIL, ELUT, BDTX, GALT, CGEN, TELO, MNPR, JATT, and ENTAShould you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Puma Biotechnology (PBYI), Instil Bio (TIL), Elutia (ELUT), Black Diamond Therapeutics (BDTX), Galectin Therapeutics (GALT), Compugen (CGEN), Telomir Pharmaceuticals (TELO), Monopar Therapeutics (MNPR), JATT Acquisition (JATT), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "pharmaceutical products" industry. Elevation Oncology vs. Puma Biotechnology Instil Bio Elutia Black Diamond Therapeutics Galectin Therapeutics Compugen Telomir Pharmaceuticals Monopar Therapeutics JATT Acquisition Enanta Pharmaceuticals Puma Biotechnology (NASDAQ:PBYI) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Does the media refer more to PBYI or ELEV? In the previous week, Elevation Oncology had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 2 mentions for Elevation Oncology and 1 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 1.45 beat Elevation Oncology's score of 0.34 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elevation Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, PBYI or ELEV? Puma Biotechnology has higher revenue and earnings than Elevation Oncology. Elevation Oncology is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPuma Biotechnology$243.57M0.55$21.59M$0.485.73Elevation OncologyN/AN/A-$45.70M-$0.82-0.71 Do analysts recommend PBYI or ELEV? Puma Biotechnology presently has a consensus target price of $7.00, suggesting a potential upside of 154.55%. Elevation Oncology has a consensus target price of $7.20, suggesting a potential upside of 1,141.38%. Given Elevation Oncology's higher possible upside, analysts clearly believe Elevation Oncology is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Elevation Oncology 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PBYI or ELEV more profitable? Puma Biotechnology has a net margin of 9.56% compared to Elevation Oncology's net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat Elevation Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Puma Biotechnology9.56% 41.60% 10.71% Elevation Oncology N/A -59.73%-40.05% Do institutionals & insiders believe in PBYI or ELEV? 61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are owned by institutional investors. 23.7% of Puma Biotechnology shares are owned by insiders. Comparatively, 8.1% of Elevation Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, PBYI or ELEV? Puma Biotechnology has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Does the MarketBeat Community believe in PBYI or ELEV? Puma Biotechnology received 517 more outperform votes than Elevation Oncology when rated by MarketBeat users. However, 75.00% of users gave Elevation Oncology an outperform vote while only 67.07% of users gave Puma Biotechnology an outperform vote. CompanyUnderperformOutperformPuma BiotechnologyOutperform Votes55067.07% Underperform Votes27032.93% Elevation OncologyOutperform Votes3375.00% Underperform Votes1125.00% SummaryPuma Biotechnology beats Elevation Oncology on 10 of the 16 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELEV vs. The Competition Export to ExcelMetricElevation OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.29M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-0.7146.7391.3417.19Price / SalesN/A411.851,116.63116.80Price / CashN/A182.1042.5837.86Price / Book0.453.894.794.78Net Income-$45.70M-$42.21M$120.07M$225.60M7 Day Performance-8.82%-2.14%-1.90%-1.24%1 Month Performance-5.20%4.21%11.43%3.06%1 Year Performance30.04%18.40%30.59%16.50% Elevation Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELEVElevation Oncology1.9868 of 5 stars$0.58-7.3%$7.20+1,141.4%+26.0%$34.29MN/A-0.7140Analyst ForecastPBYIPuma Biotechnology3.9481 of 5 stars$3.02+4.9%$7.00+131.8%-30.0%$148.25M$243.57M6.42185Positive NewsTILInstil Bio2.8565 of 5 stars$22.28+1.4%$145.00+550.8%+196.5%$145.40MN/A-1.9149ELUTElutia2.7375 of 5 stars$4.19+1.2%$10.00+138.7%+148.2%$144.81M$24.75M-1.59180BDTXBlack Diamond Therapeutics2.361 of 5 stars$2.54-0.8%$15.50+510.2%-16.2%$143.73MN/A-1.9290Positive NewsGap DownGALTGalectin Therapeutics1.9706 of 5 stars$2.29+8.3%$11.00+381.4%-39.2%$143.41MN/A-3.149News CoverageGap DownHigh Trading VolumeCGENCompugen1.5938 of 5 stars$1.59-1.6%$4.00+152.4%-17.3%$141.44M$59.85M80.5068TELOTelomir PharmaceuticalsN/A$4.76-8.5%N/AN/A$140.94MN/A0.001High Trading VolumeMNPRMonopar Therapeutics1.975 of 5 stars$26.68+5.1%$27.33+2.4%+1,165.4%$140.82MN/A-12.8810News CoverageGap UpJATTJATT AcquisitionN/A$8.16-24.1%N/A-51.6%$140.76MN/A0.003High Trading VolumeENTAEnanta Pharmaceuticals4.0505 of 5 stars$6.46+7.1%$19.50+201.9%-26.3%$136.91M$67.64M-1.10145 Related Companies and Tools Related Companies PBYI Alternatives TIL Alternatives ELUT Alternatives BDTX Alternatives GALT Alternatives CGEN Alternatives TELO Alternatives MNPR Alternatives JATT Alternatives ENTA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELEV) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
